Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Kim J, Shin DW, Lee J, Lee MJ, Yu YG, Lee DH, Kang TH. Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer. ACS Synth Biol. 2026 Jan 16; 15(1):309-320.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 Oct; 12(39):e01014.
-
You B, Anderson C, Cecere SC, Carrot A, Myers T, Heitz F, Sharma S, Sel?ukbiricik F, Aghajanian C, Fernebro J, Blank S, Laudani ME, Thaker PH, Yunokawa M, Willmott L, Lisyanskaya A, Hegg R, He Y, Landen C, Lin YG, Alarc?n J, Moore KN. Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial. Gynecol Oncol. 2025 Jun; 197:66-73.
-
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
-
Goh KY, Tham SC, Cheng TY, Nadarajah R, Goh RCH, Wong SL, Ho TH, Chew GK, Tan AWK, Rajesh H, Chua HL, Yong TT, Yu SL, Kang JM, Lau KW, Tay AZE, Mantoo S, Busmanis I, Chew SH, Lim TYK, Wong WL, Ng QJ, Wang J, Tay SK, Cheok CF, Lim DW, Lim EH. Cell Migration in Endometriosis Responds to Omentum-Derived Molecular Cues Similar to Ovarian Cancer. Int J Mol Sci. 2025 Feb 20; 26(5).
-
Zhang Y, Guan Y, Xiao X, Xu S, Zhu S, Cao D, Yu M, Peng P, Wang J, Wang Y, Yin R, Guo J, Gao W, Li P, Bai J, Gong Y, Xia X, Yi X, Yang L, Xiang Y. Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer. BMC Cancer. 2024 Dec 22; 24(1):1565.
-
Gui T, Cao D, Yang J, Wei Z, Xie J, Wang W, Xiang Y, Peng P. Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches. J Gynecol Oncol. 2025 07; 36(4):e53.
-
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 12; 144:103775.
-
O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRa-high platinum-sensitive ovarian cancer. Future Oncol. 2024; 20(32):2423-2436.